New Pancreatic Cancer Drug Approved, Boosting K-Bio Development Competition

The FDA approved Lasonk, a pancreatic cancer drug that nearly doubles patient survival time, prompting intensified competition among South Korean biotech companies developing targeted cancer therapies. Domestic firms like Onconic Therapeutics and Prestige Biopharma are advancing clinical trials, with ambitions for fast-track FDA approvals and expanded indications.

This Wire brief sits within Fusion42's coverage of Biotech.